必思諾B型腦膜炎雙球菌疫苗 台湾 - 中文 - 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

必思諾b型腦膜炎雙球菌疫苗

荷商葛蘭素史克藥廠股份有限公司台灣分公司 台北市中正區忠孝西路一段66號23-24樓 (86927438) - recombinant neisseria meningitidis group b nhba fusion protein (rp287-953);;recombinant neisseria meningitidis group b nada protein (rp961c);;recombinant neisseria meningitidis group b fhbp fusion protein (rp936-741);;outer membrane vesicles (omv) from neisseria meningitidis group b strain nz98/254 measured as amount of total protein containing the pora p1.4 - 懸浮注射液 - recombinant neisseria meningitidis group b nhba fusion protein (rp287-953) (8008004010) mcg; recombinant neisseria meningitidis group b nada protein (rp961c) (8008004020) mcg; recombinant neisseria meningitidis group b fhbp fusion protein (rp936-741) (8008004030) mcg; outer membrane vesicles (omv) from neisseria meningitidis group b strain nz98/254 measured as amount of total protein containing the pora p1.4 (8008004040) mcg - meningococcus b, multicomponent vaccine - 適用於2個月以上兒童及成人之主動免疫接種,以預防b型奈瑟氏腦膜炎雙球菌所引起的侵入性腦膜炎雙球菌疾病。

辅舒酮吸入气雾剂 50 ug/揿 中国 - 中文 - CFDA (药监局 - 中国食品和药物管理局)

辅舒酮吸入气雾剂 50 ug/揿

glaxosmithkline australia pty ltd. - 丙酸氟替卡松 - 吸入气雾剂 - 50 ug/揿

辅舒酮吸入气雾剂 125 ug/揿 中国 - 中文 - CFDA (药监局 - 中国食品和药物管理局)

辅舒酮吸入气雾剂 125 ug/揿

glaxosmithkline australia pty ltd. - 丙酸氟替卡松 - 吸入气雾剂 - 125 ug/揿